Note 2 - Basis of Presentation

3 Months Ended

12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Notes to Financial Statements

Basis of Accounting [Text Block]

Note 2 –  Basis of Presentation

These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, for interim financial information in accordance with the instructions to Form

10

-Q and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries. Accordingly, they do

not

include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s condensed consolidated financial statements have been reclassified to conform to the current year presentation. Operating results for the

three

months ended

March 31, 2020

are

not

necessarily indicative of the results that

may

be expected for the year ending

December 31, 2020.

There have been

no

changes to our significant accounting policies since

December 31, 2019. 

The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with annual audited consolidated financial statements and related notes as of and for the year ended

December 31, 2019

contained in our Annual Report on Form

10

-K for the year ended

December 31, 2019.

The interim unaudited condensed consolidated financial statements reflect the

1

-for-

3

reverse split of our common stock that was approved by our Board of Directors and controlling stockholders and made effective on

April 29, 2020. 

All share and per share information data herein that relates to our common stock prior to the effective date has been retroactively restated to reflect the reverse stock split.

Note

2

- Basis of Presentation

The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries (or the Company). Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

The consolidated financial statements reflect a

1

-for-

3

reverse split of our common stock that was approved by our Board of Directors and controlling stockholders and made effective on

April 29, 2020. 

All share and per share information data herein that relates to our common stock prior to the effective date has been retroactively restated to reflect the reverse stock split.